Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Buprenorphine: blending practice and research.

Walter Ling1, David Smith

  • 1Integrated Substance Abuse Programs, University of California, Los Angeles, 11075 Santa Monica Boulevard, Suite 200, Los Angeles, CA 90025, USA. lwalter@ucla.edu

Journal of Substance Abuse Treatment
|September 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Th17 plasticity and transition toward a pathogenic cytokine signature are regulated by cyclosporine after allogeneic SCT.

Blood advances·2018
Same author

Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.

Canadian journal of gastroenterology & hepatology·2017
Same author

Attacking the mosquito on multiple fronts: Insights from the Vector Control Optimization Model (VCOM) for malaria elimination.

PloS one·2017
Same author

Concurrent validity of the Partners in Health scale against general self-rated health in chronic conditions: A short report.

Chronic illness·2017
Same author

Ion chemistry at elevated ion-molecule interaction energies in a selected ion flow-drift tube: reactions of H<sub>3</sub>O<sup>+</sup>, NO<sup>+</sup> and O<sub>2</sub><sup>+</sup> with saturated aliphatic ketones.

Physical chemistry chemical physics : PCCP·2017
Same author

Co-occurring medical conditions in adults with Down syndrome: A systematic review toward the development of health care guidelines.

American journal of medical genetics. Part A·2017
Same journal

Call for commentaries on COVID-19.

Journal of substance abuse treatment·2024
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.

Journal of substance abuse treatment·2022
Same journal

Factors associated with the adoption of evidence-based innovations by substance use disorder treatment organizations: A study of HIV testing.

Journal of substance abuse treatment·2022
See all related articles

Buprenorphine offers a new era for treating opiate addiction, allowing general medical practitioners to offer medication-assisted treatment. Its unique properties facilitate integration, but require shifts in understanding and attitude.

Area of Science:

  • Addiction Medicine
  • Pharmacology
  • Clinical Practice

Background:

  • Opiate addiction pharmacotherapy has historically lagged in clinical application.
  • Limited integration into mainstream medical practice and lack of accessible research-based medications hinder treatment.
  • Buprenorphine represents a significant advancement in addressing these challenges.

Purpose of the Study:

  • To highlight the transformative potential of buprenorphine in opiate addiction treatment.
  • To discuss the factors facilitating and hindering its clinical integration.
  • To emphasize the need for attitudinal and systemic changes for successful implementation.

Main Methods:

  • Review of current challenges in opiate addiction pharmacotherapy.
  • Analysis of buprenorphine's pharmacological properties and clinical advantages.

Related Experiment Videos

  • Discussion of implementation requirements for widespread adoption.

    • Main Results:

    • Buprenorphine's unique pharmacological profile (high patient acceptance, safety, ease of administration) supports clinical integration.
    • It enables treatment of opiate addiction in general medical settings, a novel approach.
    • Successful integration hinges on overcoming barriers in clinician, policymaker, and societal perspectives.

    Conclusions:

    • Buprenorphine is poised to revolutionize opiate addiction pharmacotherapy.
    • Its availability marks a paradigm shift, enabling broader access to evidence-based treatment.
    • Achieving widespread success necessitates a concerted effort to adapt medical practices and societal views.